KRW 1446.0
(-0.69%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 5.47 Billion KRW | 42.24% |
2022 | 3.85 Billion KRW | 1518.2% |
2021 | 237.91 Million KRW | 84.92% |
2020 | 128.66 Million KRW | -58.42% |
2019 | 309.41 Million KRW | 0.0% |
2018 | - KRW | 0.0% |
2017 | - KRW | 0.0% |
2016 | - KRW | 0.0% |
2015 | - KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 5.72 Billion KRW | 4.55% |
2024 Q2 | 2.28 Billion KRW | -60.06% |
2023 Q2 | 3.85 Billion KRW | 0.0% |
2023 Q1 | 3.85 Billion KRW | 0.0% |
2023 FY | 5.47 Billion KRW | 42.24% |
2023 Q4 | 5.47 Billion KRW | 10.18% |
2023 Q3 | 4.97 Billion KRW | 29.09% |
2022 FY | 3.85 Billion KRW | 1518.2% |
2022 Q4 | 3.85 Billion KRW | -48.67% |
2022 Q3 | 7.5 Billion KRW | 0.0% |
2022 Q2 | 7.5 Billion KRW | 3886.4% |
2022 Q1 | 188.13 Million KRW | -20.92% |
2021 Q2 | 73.99 Million KRW | -38.5% |
2021 Q3 | 305.68 Million KRW | 313.12% |
2021 FY | 237.91 Million KRW | 84.92% |
2021 Q4 | 237.91 Million KRW | -22.17% |
2021 Q1 | 120.32 Million KRW | -80.06% |
2020 Q3 | 669.95 Million KRW | 0.0% |
2020 FY | 128.66 Million KRW | -58.42% |
2020 Q1 | - KRW | -100.0% |
2020 Q4 | 603.32 Million KRW | -9.95% |
2019 Q4 | 309.41 Million KRW | 0.0% |
2019 FY | 309.41 Million KRW | 0.0% |
2018 FY | - KRW | 0.0% |
2017 FY | - KRW | 0.0% |
2016 FY | - KRW | 0.0% |
2015 FY | - KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 367.49 Million KRW | -1390.128% |
InBody Co.,Ltd | 3.63 Billion KRW | -50.6% |
Curexo Inc. | 1.48 Billion KRW | -267.981% |
Seegene, Inc. | 1.42 Billion KRW | -284.71% |
i-SENS, Inc. | 45.74 Billion KRW | 88.03% |
Ray Co., Ltd. | 155.4 Million KRW | -3423.856% |
Sugentech Inc. | 240 Million KRW | -2181.697% |
L&C Bio Co., Ltd | 541.32 Million KRW | -911.615% |